ASP Isotopes Inc. (NASDAQ:ASPI – Get Free Report)’s stock price dropped 8.7% during trading on Monday . The company traded as low as $5.30 and last traded at $5.2960. Approximately 1,883,470 shares changed hands during trading, a decline of 62% from the average daily volume of 4,961,813 shares. The stock had previously closed at $5.80.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on ASPI shares. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a report on Friday, March 27th. Canaccord Genuity Group reiterated a “buy” rating and set a $11.00 price objective on shares of ASP Isotopes in a research report on Tuesday, April 14th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, ASP Isotopes presently has an average rating of “Hold” and a consensus target price of $13.00.
Read Our Latest Stock Analysis on ASP Isotopes
ASP Isotopes Stock Performance
ASP Isotopes (NASDAQ:ASPI – Get Free Report) last issued its quarterly earnings results on Friday, April 10th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.70). ASP Isotopes had a negative net margin of 734.14% and a negative return on equity of 161.55%. The business had revenue of $33.32 million during the quarter, compared to analyst estimates of $2.03 million.
Insider Activity at ASP Isotopes
In other ASP Isotopes news, COO Robert Ainscow sold 25,000 shares of ASP Isotopes stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $4.51, for a total value of $112,750.00. Following the completion of the sale, the chief operating officer owned 1,512,817 shares in the company, valued at $6,822,804.67. The trade was a 1.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Duncan Moore sold 11,642 shares of the stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $5.21, for a total transaction of $60,654.82. Following the transaction, the director owned 1,044,928 shares in the company, valued at approximately $5,444,074.88. The trade was a 1.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 90,704 shares of company stock worth $463,252. 14.40% of the stock is currently owned by insiders.
Hedge Funds Weigh In On ASP Isotopes
Several institutional investors and hedge funds have recently bought and sold shares of ASPI. ProShare Advisors LLC boosted its holdings in shares of ASP Isotopes by 12.4% in the 3rd quarter. ProShare Advisors LLC now owns 13,101 shares of the company’s stock valued at $126,000 after purchasing an additional 1,448 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its position in shares of ASP Isotopes by 8.3% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,056 shares of the company’s stock worth $203,000 after buying an additional 1,622 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in ASP Isotopes by 9.9% in the second quarter. The Manufacturers Life Insurance Company now owns 20,840 shares of the company’s stock valued at $153,000 after acquiring an additional 1,878 shares during the last quarter. Legal & General Group Plc grew its position in ASP Isotopes by 30.4% during the third quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock valued at $81,000 after acquiring an additional 1,953 shares during the period. Finally, BNP Paribas Financial Markets grew its position in ASP Isotopes by 84.9% during the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after acquiring an additional 2,548 shares during the period. Institutional investors and hedge funds own 16.80% of the company’s stock.
About ASP Isotopes
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.
Featured Stories
- Five stocks we like better than ASP Isotopes
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for ASP Isotopes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASP Isotopes and related companies with MarketBeat.com's FREE daily email newsletter.
